Back
Speaker illustration

undefined undefined undefined

Presentations

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

Event: Heart Failure 2025

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Advances in heart failure therapeutics

Access
Like
Thumbnail

Effect of guideline-recommended medical therapy according to blood urea nitrogen

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: ePosters in chronic heart failure - treatment 5

Access
Like
Thumbnail

Effect of neprilysin inhibition on blood urea nitrogen creatinine ratio in HFrEF : comparison of the solvd and paradigm-hf trials

Event: Heart Failure 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Heart failure with reduced ejection fraction (HFrEF) 1

Access
Like
Thumbnail

Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: Insights from PARADIGM-HF

Event: ESC Congress 2022

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Chronic heart failure - The kidney and heart failure

Access
Like
Thumbnail

Left ventricular outflow indices and sacubitril/valsartan up-titration: role of stroke volume index

Event: Heart Failure 2021

Topic: Pharmacotherapy

Session: ePoster session

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources